Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04249947 · ClinicalTrials.gov registry record · Phase 1

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

A Phase 1 study, sponsored by Poseida Therapeutics.

Terminated
Registry status
Phase 1
Development phase
40
Enrollment target

NCT04249947: Clinical Trial Phase 1 study, sponsored by Poseida Therapeutics.

NCT04249947 is a Phase 1 study that was terminated before completion, run by Poseida Therapeutics. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04249947, a Phase 1 study, was terminated before completion, sponsored by Poseida Therapeutics.

TERMINATED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

Primary Outcome

Incidence and severity of treatment-emergent adverse events

Interventions

  • DRUG Rimiducid
  • BIOLOGICAL P-PSMA-101 CAR-T cells

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-02-28
Est. Completion 2024-09-30
Phase Phase 1
Poseida Therapeutics

6 total trials

Why NCT04249947 stopped before completion

NCT04249947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which Rimiducid is the first listed.

NCT04249947 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04249947 about?

NCT04249947 is a clinical study titled "P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)". An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

What is the current status of trial NCT04249947?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-02-28. Estimated completion is 2024-09-30.

What interventions are being tested in trial NCT04249947?

The interventions under investigation include: Rimiducid (DRUG), P-PSMA-101 CAR-T cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT04249947?

This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04249947's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04249947, the US trial registry maintained by the National Library of Medicine. NCT04249947 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.